March 7-10, 2019
Fontainebleau Miami Beach
4441 Collins Avenue
Miami Beach, FL 33140

The optimal care of patients with breast cancer is rapidly changing and becoming increasingly complex as a result of advances in all aspects of management, including screening, molecular/genetic testing, detection, primary treatments (ie, surgery, radiation therapy, and systemic therapies), and patient support strategies. For 36 years, the multidisciplinary Miami Breast Cancer Conference^® has been bringing together surgical, medical, and radiation oncologists, as well as geneticists, pathologists, radiologists, and supportive care specialists, with the aim of fostering your awareness of state-of-the-art treatments for all stages and subtypes of breast cancer, providing you with expert perspectives on areas of clinical uncertainty or controversy, and encouraging you to engage in cross-team cooperation in your clinic. This year will be no different and will also include a patient communication workshop, specialized programming on issues related to young women with breast cancer, and a frank discussion about physician burnout. Please join us at the 36th Annual Miami Breast Cancer Conference^®.

• Network with your peers
• Ask world-renowned thought leaders your important questions
• Obtain clarity on areas of clinical uncertainty and controversy that you encounter in your practice
• Gain a higher level of understanding of complex data sets
• Learn how to apply the latest evidence, therapies, and strategies in your practice, including molecular, genetic, and genomic information

The 36th Annual Miami Breast Cancer Conference^®(MBC) is supported by educational grants from AbbVie Inc., AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Genentech, Inc., Genomic Health, Inc., Lilly, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, Inc., and Seattle Genetics, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Physicians' Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC, designates this live activity for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 26.0 Contact Hours.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This activity provides Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit http://www.absurgery.org

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.

• Incorporate molecular and genomic biomarkers, multi-gene prognostic assays, and tumor subtype information, in appropriate patients to inform clinical decision-making and optimize outcomes for individual patients
• Summarize expert guidelines and evidence from clinical trials that supports the use of genomic and molecular tools to individualize and inform treatment decisions for patients with early and advanced stages of breast cancer
• Coordinate evidence-based multimodal treatment strategies, integrating surgery, radiation, and systemic therapy when appropriate, to optimize outcomes for patients with non-metastatic breast cancer
• Implement multidisciplinary strategies to prevent, mitigate, or manage treatment-related adverse events for patients with breast cancer
• Integrate recent clinical trial data and expert guidelines into evolving treatment standards in order to provide state-of-the-art care for patients with breast cancer

Don’t miss the Thursday Mini-Symposium at the 36th Annual Miami Breast Cancer Conference^®, now in a new format! For years, the MBC Mini-Symposium has been a popular educational add-on option. In 2019, this special session will truly follow the format of the Tumor Boards taking place at cancer care institutions around the world. Throughout the day, a series of 15 to 20 breast cancer patient cases will be presented, each highlighting an important clinical challenge being faced by breast cancer care providers like you. A world-class multidisciplinary clinical team, composed of members of the MBC faculty, will share their approaches and perspectives for the questions at hand in the context of current evidence and best practices, with the ultimate goal of reaching consensus toward management. This special session, to be delivered by top experts in the field of breast cancer, was developed to be of interest to practitioners from all specialties, and will provide practical information to enhance patient care in your clinic.

If your schedule allows, we at Physicians' Education Resource hope you will plan to attend and take advantage of this valuable extra session!

Note: Separate registration is required.

Patrick I. Borgen, MD
Chair, Department of Surgery
Maimonides Medical Center
Brooklyn, NY